Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034845 | 0.94 | PKM (0.57) | L3MBTL1PKMALDH1A1LMNAMAPT | |
| SCHEMBL6035836 | 0.85 | L3MBTL1 (0.52) | L3MBTL1PKMALDH1A1LMNAMAPT | |
| SCHEMBL2508617 | 0.83 | L3MBTL1 (0.53) | L3MBTL1PKMALDH1A1LMNAMAPT | |
| SCHEMBL3408351 | 0.81 | PKM (0.54) | PKMALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL2933388 | 0.80 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL16064376 | 0.80 | PKM (0.52) | L3MBTL1PKMALDH1A1LMNAMAPT | |
| SCHEMBL25941353 | 0.79 | ALDH1A1 (0.65) | L3MBTL1PKMALDH1A1MAPTPOLB | |
| SCHEMBL6034241 | 0.79 | PKM (0.58) | L3MBTL1PKMALDH1A1HTTPOLB | |
| SCHEMBL6035064 | 0.78 | PKM (0.56) | L3MBTL1PKMALDH1A1MAPTHTT | |
| SCHEMBL2375629 | 0.77 | ATM (0.54) | L3MBTL1PKMALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | L3MBTL1 3906/4885PKM 3394/4885ALDH1A1 150/4885 |
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | L3MBTL1 3906/4885PKM 3394/4885ALDH1A1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.